Delcath Systems, Inc.

DCTH • Medical - Devices

$14.76

▲ +0.39 (+2.71%)

Current price

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$586.88M

Growth

—

Cash Flow

1/5

Trend

Volatile

Evidence

Positive revenue growth · 47.9%Positive free cash flow · 0.59Manageable debt level · 0.01Healthy liquidity · 10.92Expensive earnings multiple · 134

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:26 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$14.76

Change2.71%

Shares Out39.76M

Market Cap$586.88M

Enterprise Value$493.44M

52W Range8.12 - 15.62

Beta0.49

P/E1,103.16

P/S6.15

P/B4.84

P/FCF32.98

EV/Sales5.17

Price$14.76

Change2.71%

Shares Out39.76M

Market Cap$586.88M

Enterprise Value$493.44M

52W Range8.12 - 15.62

Beta0.49

P/E1,103.16

P/S6.15

P/B4.84

P/FCF32.98

EV/Sales5.17

EV/EBITDA510.81

EV/FCF27.73

Earnings Yield0.09%

FCF Yield3.03%

Dividend Yield0.00%

Gross Margin86.16%

Oper. Margin0.77%

Profit Margin3.17%

Debt/Eq0.01

Current Ratio10.92

Quick Ratio9.98

Target$24.50

Target Upside65.99%

Target Median$24.50

Target Range17.00 - 32.00

Volume2.99M

Avg Volume467.44K

EPS Surprise0.06

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

40/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

53/100

Why this score▼

Positive revenue growth · 47.9%Positive free cash flow · 0.59Manageable debt level · 0.01Healthy liquidity · 10.92Expensive earnings multiple · 134

Analyst view

Analyst sentiment and price target

DCTH

Analyst sentiment

Based on 11 analyst votes · 2026-10-21

82/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$17.00

Mean

$25.33

Median

$27.00

High

$32.00

Company Overview

IPO: 5/3/2018

Industry: Medical - Devices

P/B i: 4.84

Debt / Equity i: 0.01

Operating Margin: 0.77%

Net Margin: 3.17%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.01

Current Ratio: 10.92

Quick Ratio: 9.98

Status: Good

Insider Transactions

Recent executive and insider activity

Aharon Gil

Transaction: 05/13/2026

BUY

Change

+22,500

Price

$11.61

Filing

05/14/2026

Type

BUY

SALAMON STEVEN A J

Transaction: 05/13/2026

BUY

Change

+22,500

Price

$11.61

Filing

05/14/2026

Type

BUY

CZEREPAK ELIZABETH

Transaction: 05/13/2026

BUY

Change

+22,500

Price

$11.61

Filing

05/14/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Aharon Gil	BUY	+22,500	$11.61	05/13/2026	05/14/2026
SALAMON STEVEN A J	BUY	+22,500	$11.61	05/13/2026	05/14/2026
CZEREPAK ELIZABETH	BUY	+22,500	$11.61	05/13/2026	05/14/2026
Martell Bridget A	BUY	+22,500	$11.61	05/13/2026	05/14/2026
Sylvester John Richard	BUY	+22,500	$11.61	05/13/2026	05/14/2026
Pennell Sandra	BUY	+5,533	$9.04	03/06/2026	03/06/2026
MICHEL GERARD J	BUY	+11,200	$8.96	03/02/2026	03/03/2026
MICHEL GERARD J	BUY	+97,500	Not reported	02/17/2026	02/18/2026
MICHEL GERARD J	BUY	+195,000	$9.40	02/17/2026	02/18/2026
Rook Martha S.	BUY	+28,250	Not reported	02/17/2026	02/18/2026
Rook Martha S.	BUY	+56,500	$9.40	02/17/2026	02/18/2026
Vukovic Vojo	BUY	+28,250	Not reported	02/17/2026	02/18/2026
Vukovic Vojo	BUY	+56,500	$9.40	02/17/2026	02/18/2026
Pennell Sandra	BUY	+28,250	Not reported	02/17/2026	02/18/2026
Pennell Sandra	BUY	+56,500	$9.40	02/17/2026	02/18/2026
Muir Kevin	BUY	+28,250	Not reported	02/17/2026	02/18/2026
Muir Kevin	BUY	+56,500	$9.40	02/17/2026	02/18/2026
Hoffman David L.	BUY	+28,250	Not reported	02/17/2026	02/18/2026
Hoffman David L.	BUY	+56,500	$9.40	02/17/2026	02/18/2026
Sylvester John Richard	BUY	+4,386	$8.89	11/21/2025	11/25/2025

About the Company

Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.

Source - link

Peers

AGL BWAY CERS MASS NAKA NPCE RXST SENS SMLR TCMD

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The Company also highlighted the publication of an independent, investigator-led analysis of percutaneous hepatic perfusion (PHP) w.

Business Wire

Analysts Set Delcath Systems, Inc. (NASDAQ:DCTH) PT at $23.17

Shares of Delcath Systems, Inc. (NASDAQ: DCTH - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued

Defense World

Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?

Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.

Zacks Investment Research

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 34,00.

Business Wire

Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH

VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	-0.094	-0.03	0.064
2026-02-26	-0.06299	-0.05	0.01299
2025-11-04	0.02	0.02	0
2025-08-06	0.026	0.07	0.044
2025-05-08	0.1	0.03	-0.07
2025-03-06	-0.1	0.05	0.15
2024-11-08	-0.13	-0.03	0.1
2024-08-05	-0.34	-0.48	-0.14
2024-05-14	-0.43	-0.43	0
2024-03-26	-0.67	-0.48	0.19
2023-11-13	-0.51	-0.61	-0.1
2023-08-09	-0.67	-0.58	0.09